搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號 規(guī)格
Recombinant Methanothermobacter thermautotrophicus Putative ribonuclease VapC2 (vapC2) CSB-YP521479MSR
CSB-EP521479MSR
CSB-BP521479MSR
CSB-MP521479MSR
CSB-EP521479MSR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanothermobacter thermautotrophicus 2-phosphoglycerate kinase (pgk2) CSB-YP521480MSR
CSB-EP521480MSR
CSB-BP521480MSR
CSB-MP521480MSR
CSB-EP521480MSR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanothermobacter thermautotrophicus RNA 3'-terminal phosphate cyclase (rtcA) CSB-YP521481MSR
CSB-EP521481MSR
CSB-BP521481MSR
CSB-MP521481MSR
CSB-EP521481MSR-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Uncharacterized protein AF_2339 (AF_2339) CSB-YP521482DOC
CSB-EP521482DOC
CSB-BP521482DOC
CSB-MP521482DOC
CSB-EP521482DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Uncharacterized protein AF_2330 (AF_2330) CSB-YP521483DOC
CSB-EP521483DOC
CSB-BP521483DOC
CSB-MP521483DOC
CSB-EP521483DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Cobalamin synthase 2 (cobS2), partial CSB-YP521484DOC1
CSB-EP521484DOC1
CSB-BP521484DOC1
CSB-MP521484DOC1
CSB-EP521484DOC1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Nicotinamide-nucleotide adenylyltransferase (AF_2315) CSB-YP521485DOC
CSB-EP521485DOC
CSB-BP521485DOC
CSB-MP521485DOC
CSB-EP521485DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Pyruvoyl-dependent arginine decarboxylase 1 (pdaD1) CSB-YP521486DOC
CSB-EP521486DOC
CSB-BP521486DOC
CSB-MP521486DOC
CSB-EP521486DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Uncharacterized protein AF_2292 (AF_2292) CSB-YP521487DOC
CSB-EP521487DOC
CSB-BP521487DOC
CSB-MP521487DOC
CSB-EP521487DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus 30S ribosomal protein S4P (rps4p) CSB-YP521488DOC
CSB-EP521488DOC
CSB-BP521488DOC
CSB-MP521488DOC
CSB-EP521488DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Imidazole glycerol phosphate synthase subunit HisH (hisH) CSB-YP521489DOC
CSB-EP521489DOC
CSB-BP521489DOC
CSB-MP521489DOC
CSB-EP521489DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Alanine--tRNA ligase (alaS), partial CSB-YP521490DOC
CSB-EP521490DOC
CSB-BP521490DOC
CSB-MP521490DOC
CSB-EP521490DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Thermosome subunit alpha (thsA), partial CSB-YP521491DOC
CSB-EP521491DOC
CSB-BP521491DOC
CSB-MP521491DOC
CSB-EP521491DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus UPF0104 membrane protein AF_2231 (AF_2231), partial CSB-YP521492DOC1
CSB-EP521492DOC1
CSB-BP521492DOC1
CSB-MP521492DOC1
CSB-EP521492DOC1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Valine--tRNA ligase (valS), partial CSB-YP521493DOC
CSB-EP521493DOC
CSB-BP521493DOC
CSB-MP521493DOC
CSB-EP521493DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Uncharacterized protein AF_2210 (AF_2210) CSB-YP521494DOC
CSB-EP521494DOC
CSB-BP521494DOC
CSB-MP521494DOC
CSB-EP521494DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Uncharacterized protein AF_2201 (AF_2201) CSB-YP521495DOC
CSB-EP521495DOC
CSB-BP521495DOC
CSB-MP521495DOC
CSB-EP521495DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Uncharacterized protein AF_2191 (AF_2191), partial CSB-YP521496DOC1
CSB-EP521496DOC1
CSB-BP521496DOC1
CSB-MP521496DOC1
CSB-EP521496DOC1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Succinyl-CoA ligase [ADP-forming] subunit alpha 2 (sucD2) CSB-YP521497DOC
CSB-EP521497DOC
CSB-BP521497DOC
CSB-MP521497DOC
CSB-EP521497DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Archaeoglobus fulgidus Uncharacterized protein AF_2172 (AF_2172) CSB-YP521498DOC
CSB-EP521498DOC
CSB-BP521498DOC
CSB-MP521498DOC
CSB-EP521498DOC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時,你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實驗更有可能成功。但是如果你做了錯誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗總結(jié)出了幾個有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://www.pptc.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們在線留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>